Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.59 |
| ▸ | MEN1 | O00255 | 4/20 | 0.59 |
| ▸ | APAF1 | O14727 | 1/20 | 0.59 |
| ▸ | TDP2 | O95551 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | CASP3 | P42574 | 1/20 | 0.59 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.59 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.59 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | MPI | P34949 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | SLC40A1 | Q9NP59 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29937553 | 0.84 | KDM4E (0.61) | KMT2AMEN1APAF1TDP2ALDH1A1 | |
| SCHEMBL3558147 | 0.84 | KDM4E (0.61) | KMT2AMEN1APAF1TDP2ALDH1A1 | |
| SCHEMBL29933523 | 0.84 | KDM4E (0.46) | KMT2AMEN1APAF1TDP2ALDH1A1 | |
| SCHEMBL3712379 | 0.84 | KDM4E (0.46) | KMT2AMEN1APAF1TDP2ALDH1A1 | |
| SCHEMBL196848 | 0.83 | KMT2A (0.68) | KMT2AMEN1APAF1TDP2ALDH1A1 | |
| SCHEMBL19990071 | 0.83 | KDM4E (0.70) | KMT2AMEN1ALDH1A1MAPTKDM4E | |
| SCHEMBL20563437 | 0.77 | KDM4E (0.47) | KMT2AMEN1APAF1TDP2ALDH1A1 | |
| SCHEMBL18980424 | 0.76 | KMT2A (0.59) | KMT2AMEN1APAF1TDP2ALDH1A1 | |
| SCHEMBL30312616 | 0.76 | KMT2A (0.59) | KMT2AMEN1APAF1TDP2ALDH1A1 | |
| SCHEMBL16798532 | 0.76 | KMT2A (0.59) | KMT2AMEN1APAF1TDP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289826-A1 | PLPRO PROTEIN INHIBITOR, AND PREPARATION METHOD AND APPLICATION THEREOF | TSINGHUA UNIVERSITY (CN) | 2025-09-18 | — | — | US | disclosed |
| WO-2025098509-A1 | PYRROLIDINE DERIVATIVE, PHARMACEUTICAL COMPOSITION AND USE THEREOF IN MEDICINE | 康百达（四川）生物医药科技有限公司 | 2025-05-15 | — | — | WO | disclosed |
| EP-4055014-B1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | YUHAN CORP (KR) | 2025-04-30 | — | — | EP | disclosed |
| US-20250059157-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2025-02-20 | — | — | US | disclosed |
| EP-4509494-A1 | PLPRO PROTEIN INHIBITOR, AND PREPARATION METHOD AND APPLICATION THEREOF | Tsinghua University (CN) | 2025-02-19 | — | — | EP | disclosed |
| EP-4466260-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | Astrazeneca AB (SE) | 2024-11-27 | — | — | EP | disclosed |
| CN-118574821-A | Compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2024-08-30 | — | — | CN | disclosed |
| CN-114867719-B | Pyrrolidine and piperidine compounds | 柳韩洋行 | 2024-06-25 | — | — | CN | disclosed |
| US-11891369-B2 | Compounds for binding proprotein convertase subtilisin/kexin type 9 | SRX CARDIO, LLC (US) | 2024-02-06 | — | — | US | disclosed |
| WO-2023208171-A1 | PLPRO PROTEIN INHIBITOR, AND PREPARATION METHOD AND APPLICATION THEREOF | 清华大学 | 2023-11-02 | — | — | WO | disclosed |
| US-8436015-B2 | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | MERCK SHARP & DOHME CORP. (US) | 2013-05-07 | — | — | US | disclosed |
| US-8436015-B2 | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | MERCK SHARP & DOHME CORP. (US) | 2013-05-07 | — | — | US | disclosed |
| US-8436015-B2 | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | MERCK SHARP & DOHME CORP. (US) | 2013-05-07 | — | — | US | disclosed |
| EP-2346830-A1 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | Merck Sharp & Dohme Corp. (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20110172256-A1 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK SHARP & DOHME LLC | 2011-07-14 | — | — | US | disclosed |
| US-20110172256-A1 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK SHARP & DOHME LLC | 2011-07-14 | — | — | US | disclosed |
| US-20110172256-A1 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK SHARP & DOHME LLC | 2011-07-14 | — | — | US | disclosed |
| WO-2010094643-A1 | QUINOLINE DERIVATIVES AND THEIR USES FOR RHINITIS AND URTICARIA | GLAXO GROUP LIMITED (GB) | 2010-08-26 | — | — | WO | disclosed |
| WO-2010030722-A1 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK SHARP & DOHME CORP. (US) | 2010-03-18 | — | — | WO | disclosed |
| WO-2010030722-A1 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK SHARP & DOHME CORP. (US) | 2010-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891369-B2 | Compounds for binding proprotein convertase subtilisin/kexin type 9 | PCSK9, PCSK6, PCSK7 | KMT2A 3815/4885MEN1 1103/4885APAF1 131/4885 |
| US-20110172256-A1 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | GCGR, GLP1R, GPR119 | KMT2A 4294/4885MEN1 1614/4885APAF1 3488/4885 |
| US-20250059157-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | KMT2A 1063/4885MEN1 4517/4885APAF1 1262/4885 |
| US-20250289826-A1 | PLPRO PROTEIN INHIBITOR, AND PREPARATION METHOD AND APPLICATION THEREOF | ACE, PLP2, ACE2 | KMT2A 2539/4885MEN1 4500/4885APAF1 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.